Valeant Pharmaceuticals Intl Inc (VRX) Rating Reiterated by Royal Bank Of Canada
Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada in a report released on Monday. They presently have a C$46.00 price objective on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 42.90% from the company’s current price.
Other equities research analysts also recently issued reports about the company. TD Securities decreased their price objective on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a research report on Wednesday, June 8th. Scotiabank decreased their price objective on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating on the stock in a research report on Monday, July 25th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of C$38.67.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.44 on Monday. The company’s 50 day moving average price is $36.77 and its 200 day moving average price is $35.56. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $240.40. The company’s market capitalization is $11.27 billion.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.